Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies

BACKGROUND: Cervical cancer is now considered the second leading cause of death among women worldwide, and its incidence has reached alarming levels, especially in developing countries. Similarly, high grade squamous intraepithelial lesion (HSIL), the precursor stage for cervical cancer, represents...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Solares, Ana M, Santana, Agueda, Baladrón, Idania, Valenzuela, Carmen, González, Carlos A, Díaz, Alina, Castillo, Dagnelia, Ramos, Thelvia, Gómez, Roberto, Alonso, Daniel F, Herrera, Luis, Sigman, Hugo, Perea, Silvio E, Acevedo, Boris E, López-Saura, Pedro
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2009
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2689241/
https://ncbi.nlm.nih.gov/pubmed/19439079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-146
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items